Evaluation of the effect of low-dose naltrexone in patients with Trigeminal Neuralgia and Chronic migraine patients

Phase 3

• Conditions: G50.0; G43.7; Condition 1: Trigeminal Neuralgia. Condition 2: Chronic Migraine.; Trigeminal neuralgia; Chronic migraine without aura

• Registration Number: IRCT20171109037332N2
• Lead Sponsor: Kerman University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 2 May 2022

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

According to ICHD3 criteria, they are diagnosed with TN or chronic headache.
Be over 18 years old
Have the necessary cooperation to participate in the study.

Exclusion Criteria

Patient non-cooperation
The patient is pregnant or breastfeeding.
If the patient uses opioid analgesics or inhales opioids
If the patient regularly uses anti-inflammatory drugs.
Known allergy or reaction to naltrexone
If the patient consumes alcohol and can not refrain from consuming it during the study.
The patient has rheumatic or autoimmune diseases
The patient has been diagnosed with a mental illness that disrupts his or her collaboration in the study.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ow-dose naltrexone, chronic migraine, trigeminal neuralgia. Timepoint: Before the intervention and every day during the intervention. Method of measurement: VAS questionnaire.